organoid drug screening
Testing therapeutic agents on three-dimensional tumor models derived from patient samples to predict treatment response.
Full Definition
Organoid drug screening involves the use of patient-derived three-dimensional cell culture models that recapitulate key features of the original tumor to test drug sensitivity and resistance patterns. These organoids maintain tumor architecture, cellular diversity, and genetic characteristics more faithfully than traditional two-dimensional cell cultures. Drug screening on organoids can potentially predict which treatments are most likely to be effective for individual patients, supporting personalized treatment selection. This approach is particularly valuable for rare cancers or cases where standard treatment options have been exhausted. Organoid screening represents a functional approach to precision medicine, complementing genomic profiling by providing direct evidence of drug efficacy.
Usage
Usage note: Specify culture timeframe and drug panel composition when describing methodologies
In Context
- "Organoid drug screening identified unexpected sensitivity to a combination therapy." — Personalized medicine consultation
- "The organoid screening platform tested 150 compounds against the patient's tumor sample." — Precision oncology service description